Reported about 1 year ago
Xuanjie, a stem cell company that went public on the 'OTC' last year, recently celebrated the passage of the 'Regenerative Medicine Act' and 'Regenerative Medicine Preparation Regulations'. The company faced challenges in clinical trials and marketing due to the pandemic, but with the leadership of General Manager Wu Shiyang, the team successfully overcame obstacles. Xuanjie aims to produce 'Allogeneic Stem Cell Preparations' with a focus on regenerative medicine, and plans to expand collaborations with universities for research commercialization. Wu Shiyang also urges the government to support the regenerative medicine industry and enhance talent cultivation in the field.
Source: YAHOO